This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
NVO Stock Down as Medicare Selects Semaglutide Drugs for Price Cuts
by Zacks Equity Research
Novo Nordisk stock falls as Medicare selects its marketed semaglutide medicines catering to T2D and obesity for price negotiations in 2025.
Amgen's Lumakras Gets FDA Nod for Expanded Use in Colorectal Cancer
by Zacks Equity Research
The FDA approves Amgen's Lumakras in combination with Vectibix for treating previously treated adults with KRAS G12C-mutated metastatic colorectal cancer.
Is it a Good Idea to Invest in Stoke Therapeutics Stock Now?
by Zacks Equity Research
Here, we discuss some reasons why investing in STOK now may turn out to be a prudent move.
IBRX Stock Soars on Completing Filing for Cancer Therapy in EU & UK
by Zacks Equity Research
ImmunityBio stock rises 27% on completing the regulatory filing process in the EU and the U.K. for the Anktiva/BCG combo to treat NMIBC CIS patients.
ATRA Stock Down After FDA Issues CRL for Rare Blood Cancer Candidate
by Zacks Equity Research
Atara stock plunges 41% upon the FDA issuance of a CRL against its BLA for Ebvallo to treat EBV+ PTLD. The company is also facing a severe cash crunch.
MIRM Shares Rise 12% in a Week on Robust Preliminary 2024 Results
by Zacks Equity Research
Mirum stock rallies this week on upbeat preliminary 2024 results, the 2025 outlook and anticipated pipeline goals.
InflaRx Stock Rises 8% on Conditional EC Nod for COVID-19 Drug
by Zacks Equity Research
IFRX stock gains 8% on EC nod for Gohibic, under exceptional circumstances, to treat adult patients with COVID-19-induced ARDS.
ACAD Seeks EU Nod for Rett Syndrome Drug, Outlines 2025 Pipeline Goals (Revised)
by Zacks Equity Research
Acadia files regulatory application for trofinetide to treat Rett syndrome in EU. The company also outlines other pipeline goals for 2025-2026.
Kymera Provides Pipeline Objectives for 2025, Stock Gains
by Zacks Equity Research
KYMR outlines plans to advance its immunology candidates. As of Dec. 31, 2024, KYMR had $850 million in cash that should fund its operations into mid-2027.
ACAD Seeks EU Nod for Rett Syndrome Drug, Outlines 2025 Pipeline Goals
by Zacks Equity Research
Acadia files regulatory application for trofinetide to treat Rett syndrome in EU. The company also outlines other pipeline goals for 2025-2026.
MDGL Stock Down 10% on Disappointing Preliminary Q4 Rezdiffra Sales
by Zacks Equity Research
Madrigal stock slides 10% as the preliminary Q4 Rezdiffra sales figures failed to impress investors.
TGTX Announces 2024 Preliminary Results, 2025 Goals, Shares Rise
by Zacks Equity Research
TG Therapeutics reports preliminary fourth-quarter and full-year 2024 product revenues. It also provides revenue guidance for 2025 and other pipeline goals.
SWTX Announces 2024 Preliminary Results, 2025 Goals, Stock Down
by Zacks Equity Research
SpringWorks reports preliminary fourth-quarter and full-year 2024 product revenues. It also provides updates across the commercial portfolio and other pipelines.
Moderna Stock Plummets 17% on 2025 Sales Guidance Slash
by Zacks Equity Research
The crash in MRNA stock comes after the company slashed its outlook for 2024 and 2025 sales and also announced an expanded cost-cutting initiative.
Blueprint Stock Soars 18% on Encouraging 2025 Growth Strategy
by Zacks Equity Research
BPMC stock rallies 18% on the company's optimistic 2025 outlook encompassing Ayvakit sales growth and pipeline progress.
Biogen Offers to Buy Remaining Stake in Sage Therapeutics
by Zacks Equity Research
Biogen offers to buy the remaining stake in Sage Therapeutics for $7.22 per share. SAGE stock rises.
PCRX Stock Rises 11% on Upbeat Q4 Preliminary Product Sales
by Zacks Equity Research
Pacira stock gains 11% on better-than-expected preliminary Q4 sales figures. It also shares a strategic growth plan to drive innovation and value creation by 2030.
ITCI Stock Rises 15% on Settling Caplyta Patent Litigation With Sandoz
by Zacks Equity Research
Intra-Cellular stock gains 15% as it settles Caplyta patent litigation with Sandoz protecting the drug's exclusivity in the United States till July 1, 2040.
Amicus Posts Preliminary 2024 Results, Issues 2025 Outlook
by Zacks Equity Research
FOLD reports preliminary fourth-quarter and full-year 2024 total revenues. The company also outlines key strategic goals for 2025.
Pfizer Meets Goal in Non-Muscle Invasive Bladder Cancer Study
by Zacks Equity Research
Data from a late-stage study shows that treatment with PFE's PD-1 inhibitor when added to BCG improves outcomes in certain bladder cancer patients.
FDA Updates EXEL on Previously Scheduled ODAC Meeting for Cabozantinib
by Zacks Equity Research
EXEL's sNDA seeking approval of cabozantinib for the treatment of pancreatic neuroendocrine tumors will not be discussed at an ODAC.
SANA Stock Surges 152% in a Week on Upbeat Initial Diabetes Study Data
by Zacks Equity Research
Sana stock soars in a week following positive initial data from a first-in-human study of investigational cell therapy, UP421, in diabetes patients.
FDA Accepts J&J's Filing for Autoimmune Disease Drug Nipocalimab
by Zacks Equity Research
JNJ's filing seeks the FDA's approval for nipocalimab to treat generalized myasthenia gravis in a broad population of antibody-positive patients.
VIR Stock Up on Early Safety & Efficacy Data on Two Cancer Candidates
by Zacks Equity Research
Vir Biotechnology posts encouraging initial data from phase I studies evaluating VIR-5818 and VIR-5500 in heavily pretreated patients with various solid tumors.
NVO Stock Up 3% as UBS Upgrades Company Rating From Neutral to Buy
by Zacks Equity Research
Novo Nordisk stock gains 3% as analysts at UBS upgrade the company's rating from Neutral to Buy based on strong brand recognition of Ozempic and Wegovy.